한글목차

세계 안과용 약물 시장 규모는 2035년에 걸쳐 CAGR 7.2%로 성장할 것으로 예측됩니다.

세계 안과용 약제 시장은 몇 가지 중요한 요인에 의해 강력한 성장을 이루고 있습니다. 이 동향은 세계 인구의 고령화와 라이프 스타일의 변화로 인해 이러한 질병의 이환율이 증가하고 있기 때문에 혁신적인 약제의 필요성 증가하고 있습니다. 또한, 제약회사가 연구개발에 많은 투자를 하고, 보다 강화된 신규 치료법을 도입하고 있는 것에 의한 안과용 약제의 강력한 파이프라인도 시장의 확대를 뒷받침하고 있습니다. 개발로, 보다 적은 정밀한 치료가 실현되고 치료 옵션이 늘어나 시장의 기세가 가속화되고 있습니다.

약물의 부작용이 업계 성장의 과제가 될 가능성

국소제는 일시적인 시야의 흐림, 알레르기 반응, 시각 장애, 자통, 작열감, 가려움 등 다양한 부작용을 일으킬 수 있습니다. 시야의 변화, 심각한 두통, 터널 비전, 눈의 불쾌감, 눈 안쪽의 통증, 붓기와 분비물과 같은 눈 감염의 징후 등이 있습니다. 성장을 제한할 수 있습니다.

본 보고서에서는 세계 안과용 약제 시장을 조사했으며, 시장 개요, 시장성장에 대한 영향인자 및 시장 기회 분석, 시장 규모 추이와 예측, 각종 구분·지역/주요 국가별 상세 분석, 경쟁 정세, 주요 기업 프로파일 등을 정리했습니다.

목차

제1장 보고서 개요

제2장 주요 요약

제3장 시장 개요

• 주요 조사 결과
• 시장 역학
  • 시장 견인 요인
  • 시장 성장 억제요인
  • 시장 기회
• 새로운 동향
• Porter's Five Forces 분석
• PEST 분석
• 최근 승인

제4장 안과용 약제 시장의 분석 : 유형별

• 주요 조사 결과
• 시장 매력도 지수
• 시장 규모 추이와 예측
• 처방약
• 시판약
  • 시장 규모 추이와 예측 : 지역별
  • 시장 점유율 : 지역별

제5장 안과용 약제 시장의 분석 : 유통 채널별

• 주요 조사 결과
• 시장 매력도 지수
• 시장 규모 추이와 예측
• 병원 약국
• 약국
• 온라인 약국
  • 시장 규모 추이와 예측 : 지역별
  • 시장 점유율 : 지역별

제6장 안과용 약제 시장의 분석 : 적응증별

• 주요 조사 결과
• 시장 매력도 지수
• 시장 규모 추이와 예측
• 망막 질환
• 감염/염증/알레르기
• 안구건조증
• 녹내장
• 기타
  • 시장 규모 추이와 예측 : 지역별
  • 시장 점유율 : 지역별

제7장 안과용 약제 시장 분석 : 투여 경로별

• 주요 조사 결과
• 시장 매력도 지수
• 시장 규모 추이와 예측
• 국소제
• 비경구제
  • 시장 규모 추이와 예측 : 지역별
  • 시장 점유율 : 지역별

제8장 지역별 안과약 시장 분석

• 주요 조사 결과
• 시장 규모 추이와 예측

제9장 북미 안과용 약제 시장 분석

제10장 유럽 안과용 약제 시장 분석

제11장 아시아태평양의 안과용 약제 시장 분석

제12장 라틴아메리카 안과용 약제 시장 분석

제13장 중동 및 아프리카 안과용 약제 시장 분석

제14장 기업 프로파일

• Strategic Outlook
• Novartis AG
• Bayer AG
• Pfizer Inc.
• Bausch Lomb Corporation
• Santen Pharmaceutical Co., Ltd.
• Johnson & Johnson Services, Inc.
• Regeneron Pharmaceuticals Inc.
• AbbVie Inc.
• F. Hoffmann-La Roche Ltd
• Teva Pharmaceutical Industries Ltd.
• Apellis Pharmaceuticals
• Novaliq GmbH
• Alimera Sciences
• EyeBio
• SpliceBio
• Breye Therapeutics ApS
• Nicox
• Alcon
• Viatris Inc.
• Sun Pharmaceutical Industries Ltd.

제15장 총론·제안

• Visiongain에 의한 총론
• 참가 기업에 대한 제안

영문목차

The global Ophthalmic Drugs market is projected to grow at a CAGR of 7.2% by 2035.

The The Ophthalmic Drugs Market Report 2025-2035: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

The global ophthalmic drugs market is experiencing robust growth, driven by several key factors. Rising incidences of eye-related conditions such as glaucoma, macular degeneration, diabetic retinopathy, and dry eye syndrome are fuelling the demand for advanced pharmaceutical solutions. This trend is further supported by an aging global population and lifestyle changes that increase susceptibility to these conditions, underscoring the need for innovative drug options. A strong pipeline of new ophthalmic drugs is also bolstering market expansion, as pharmaceutical companies invest substantially in R&D to introduce enhanced and novel treatments. These active developments are set to deliver more targeted and precise therapies, improving treatment options and accelerating market momentum. With sustained innovation and continuous advancements, the global ophthalmic drugs market is expected to maintain its growth trajectory in the coming years.

Side Effects of Drugs Likely to Challenge Industry Growth

Topical ophthalmic drugs can cause a variety of side effects, including temporary vision cloudiness, allergic reactions, visual disturbances, and stinging, burning, or itching. Less common but more severe side effects include sudden vision changes, intense headaches, tunnel vision, eye discomfort, pain behind the eyes, and signs of an eye infection, such as swelling and discharge. As a result, adverse effects, particularly those associated with topical steroidal drugs, may limit market growth.

Addressing drug-related side effects in the ophthalmic drugs market, particularly in developing countries, necessitates a comprehensive strategy. This includes increasing healthcare accessibility, developing medical infrastructure, educating patients, reducing counterfeit drug circulation, and enacting stringent regulatory frameworks to ensure the safety and efficacy of ophthalmic treatments. Apellis Pharmaceuticals' drug pegcetacoplan, which was approved by the FDA for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), has raised safety concerns due to instances of intraocular inflammation (IOI), according to the American Society of Retina Specialists (ASRS). As of April 2023, the ASRS Research and Safety in Therapeutics (ReST) Committee began tracking reports of IOI, some of which resulted in severe retinal vasculitis, occlusive retinal vasculopathy, or vision loss. On 16th January 2024, a retrospective analysis revealed 14 cases of retinal vasculitis among 13 patients following their first pegcetacoplan injection, with inflammation typically manifesting around 10.5 days after the injection. Notably, retinal veins were more affected than arteries, and 57% of impacted eyes had significant vision acuity (VA) loss, with two cases necessitating enucleation due to severe complications. In addition, 43% of cases showed anterior segment neovascularisation. These findings highlight critical safety issues, emphasising the importance of continuous monitoring and real-world safety analysis of pegcetacoplan in order to better assess and manage associated risks.

What Questions Should You Ask before Buying a Market Research Report?

• How is the ophthalmic drugs market evolving?
• What is driving and restraining the ophthalmic drugs market?
• How will each ophthalmic drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2035?
• How will the market shares for each ophthalmic drugs submarket develop from 2025 to 2035?
• What will be the main driver for the overall market from 2025 to 2035?
• Will leading ophthalmic drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2035 and which geographical region will lead the market in 2035?
• Who are the leading players and what are their prospects over the forecast period?
• How will the industry evolve during the period between 2025 and 2035? What are the implications of ophthalmic drugs projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the ophthalmic drugs market?
• Where is the ophthalmic drugs market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Ophthalmic Drugs Market today, and over the next 10 years:

• Our 344-page report provides 129 tables, 178 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.
• Forecasts to 2035 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2035, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising ophthalmic drugs prices and recent developments.

Segments Covered in the Report

• Type
• Prescription Drugs
• OTC Drugs
• Indication
• Retinal Disorders
• Infection/Inflammation/Allergy
• Glaucoma
• Dry Eye
• Others
• Route of Administration
• Topical
• Parenteral
• Distribution Channel
• Hospital Pharmacies
• Drug Stores
• Online Pharmacies

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 26 leading national markets:

• North America
• U.S.
• Canada
• Europe
• Germany
• Spain
• UK
• France
• Italy
• Netherlands
• Switzerland
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Malaysia
• Singapore
• Rest of Asia Pacific
• Latin America
• Brazil
• Argentina
• Mexico
• Chile
• Rest of Latin America
• MEA
• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Ophthalmic Drugs Market 2025 to 2035, with a focus on this segment of these companies' operations.

• Leading companies and the potential for market growth
• AbbVie Inc.
• Alcon
• Alimera Sciences
• Apellis Pharmaceuticals
• Bausch + Lomb Corporation
• Bayer AG
• Breye Therapeutics ApS
• EyeBio
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson Services, Inc.
• Nicox
• Novaliq GmbH
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Santen Pharmaceutical Co., Ltd.
• SpliceBio
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

Overall world revenue for ophthalmic drugs market, 2025 to 2035 in terms of value the market will surpass US$35.0 billion in 2025, our work calculates. We predict strong revenue growth through to 2035. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

• How will the Ophthalmic Drugs Market, 2025 to 2035 report help you?
• In summary, our 340+ page report provides you with the following knowledge:
• Revenue forecasts to 2035 for Ophthalmic Drugs Market, 2025 to 2035 Market, with forecasts for type, distribution channel, indication, route of administration, each forecast at a global and regional level discover the industry's prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2035 for five regional and 26 key national markets See forecasts for the Ophthalmic Drugs Market, 2025 to 2035 market in North America, Europe, Asia-Pacific, Latin America and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market including company profiles for 21 of the major companies involved in the Ophthalmic Drugs Market, 2025 to 2035.
• Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
• Information found nowhere else
• With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Ophthalmic Drugs Market, 2025 to 2035, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

• 1.1 Objectives of the Study
• 1.2 Introduction to Ophthalmic Drugs Market
• 1.3 What This Report Delivers
• 1.4 Why You Should Read This Report
• 1.5 Key Questions Answered by This Analytical Report
• 1.6 Who is This Report for?
• 1.7 Methodology
  • 1.7.1 Market Definitions
  • 1.7.2 Market Evaluation & Forecasting Methodology
  • 1.7.3 Data Validation
    • 1.7.3.1 Primary Research
    • 1.7.3.2 Secondary Research
• 1.8 Frequently Asked Questions (FAQs)
• 1.9 Associated Visiongain Reports
• 1.10 About Visiongain

2 Executive Summary

3 Market Overview

• 3.1 Key Findings
• 3.2 Market Dynamics
  • 3.2.1 Market Driving Factors
    • 3.2.1.1 Rising Frequency and Occurrence of Eye-related Conditions
    • 3.2.1.2 Technological Advancements and Innovations
    • 3.2.1.3 Increasing Prevalence of Diabetes
    • 3.2.1.4 Presence of Strong Emerging Pipeline Drugs
  • 3.2.2 Market Restraining Factors
    • 3.2.2.1 Lack of Health Insurance in the Developing Countries
    • 3.2.2.2 Lack of Awareness Regarding the Available Treatment Options
    • 3.2.2.3 Side Effects of Drugs
    • 3.2.2.4 Patent Expiry of Blockbuster Drugs
    • 3.2.2.5 Impact of Elevated R&D Expenses and Patent Loss on Popular Pharmaceuticals
    • 3.2.2.6 Intensifying Competition in the Crowded Ophthalmic Drugs Market
  • 3.2.3 Market Opportunities
    • 3.2.3.1 Rise in Investment in Research and Development
    • 3.2.3.2 Rise in Geriatric Population
    • 3.2.3.3 Emergence of Digital Health Solutions and Telemedicine
    • 3.2.3.4 Growing Regulatory Support for Innovation in the Ophthalmic Sector
    • 3.2.3.5 E-Commerce and Online Pharmacies Unlock New Market Opportunities
• 3.3 Emerging Trends
• 3.4 Porter's Five Forces Analysis
  • 3.4.1 Bargaining Power of Suppliers
  • 3.4.2 Bargaining Power of Buyers
  • 3.4.3 Competitive Rivalry
  • 3.4.4 Threat of Substitutes
  • 3.4.5 Threat of New Entrants
• 3.5 PEST Analysis
  • 3.5.1 Political
  • 3.5.2 Economical
  • 3.5.3 Social
  • 3.5.4 Technological
• 3.6 Recent Approvals

4 Ophthalmic Drugs Market Analysis by Type

• 4.1 Key Findings
• 4.2 Type Segment: Market Attractiveness Index
• 4.3 Ophthalmic Drugs Market Size Estimation and Forecast by Type
• 4.4 Prescription Drugs
  • 4.4.1 Market Size by Region, 2025-2035 (US$ Billion)
  • 4.4.2 Market Share by Region, 2025 & 2035 (%)
• 4.5 OTC Drugs
  • 4.5.1 Market Size by Region, 2025-2035 (US$ Billion)
  • 4.5.2 Market Share by Region, 2025 & 2035 (%)

5 Ophthalmic Drugs Market Analysis by Distribution Channel

• 5.1 Key Findings
• 5.2 Distribution Channel Segment: Market Attractiveness Index
• 5.4 Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
• 5.5 Hospital Pharmacies
  • 5.5.1 Market Size by Region, 2025-2035 (US$ Billion)
  • 5.5.2 Market Share by Region, 2025 & 2035 (%)
• 5.6 Drug Stores
  • 5.6.1 Market Size by Region, 2025-2035 (US$ Billion)
  • 5.6.2 Market Share by Region, 2025 & 2035 (%)
• 5.7 Online Pharmacies
  • 5.7.1 Market Size by Region, 2025-2035 (US$ Billion)
  • 5.7.2 Market Share by Region, 2025 & 2035 (%)

6 Ophthalmic Drugs Market Analysis by Indication

• 6.1 Key Findings
• 6.2 Indication Segment: Market Attractiveness Index
• 6.3 Ophthalmic Drugs Market Size Estimation and Forecast by Indications
• 6.4 Retinal Disorders
  • 6.4.1 Market Size by Region, 2025-2035 (US$ Billion)
  • 6.4.2 Market Share by Region, 2025 & 2035 (%)
• 6.5 Infection/Inflammation/Allergy
  • 6.5.1 Market Size by Region, 2025-2035 (US$ Billion)
  • 6.5.2 Market Share by Region, 2025 & 2035 (%)
• 6.6 Dry Eye
  • 6.6.1 Market Size by Region, 2025-2035 (US$ Billion)
  • 6.6.2 Market Share by Region, 2025 & 2035 (%)
• 6.7 Glaucoma
  • 6.7.1 Market Size by Region, 2025-2035 (US$ Billion)
  • 6.7.2 Market Share by Region, 2025 & 2035 (%)
• 6.8 Others
  • 6.8.1 Market Size by Region, 2025-2035 (US$ Billion)
  • 6.8.2 Market Share by Region, 2025 & 2035 (%)

7 Ophthalmic Drugs Market Analysis by Route of Administration

• 7.1 Key Findings
• 7.2 Route of Administration Segment: Market Attractiveness Index
• 7.4 Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
• 7.5 Topical
  • 7.5.1 Market Size by Region, 2025-2035 (US$ Billion)
  • 7.5.2 Market Share by Region, 2025 & 2035 (%)
• 7.6 Parenteral
  • 7.6.1 Market Size by Region, 2025-2035 (US$ Billion)
  • 7.6.2 Market Share by Region, 2025 & 2035 (%)

8 Ophthalmic Drugs Market Analysis by Region

• 8.1 Key Findings
• 8.2 Regional Market Size Estimation and Forecast

9 North America Ophthalmic Drugs Market Analysis

• 9.1 Key Findings
• 9.2 North America Ophthalmic Drugs Market Attractiveness Index
• 9.3 North America Ophthalmic Drugs Market by Country, 2025, 2030 & 2035 (US$ Billion)
• 9.4 North America Ophthalmic Drugs Market Size Estimation and Forecast by Country
• 9.5 North America Ophthalmic Drugs Market Size Estimation and Forecast by Type
• 9.6 North America Ophthalmic Drugs Market Size Estimation and Forecast by Distribution channel
• 9.7 North America Ophthalmic Drugs Market Size Estimation and Forecast by Indications
• 9.8 North America Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
• 9.9 U.S. Ophthalmic Drugs Market Analysis
• 9.10 Canada Ophthalmic Drugs Market Analysis

10 Europe Ophthalmic Drugs Market Analysis

• 10.1 Key Findings
• 10.2 Europe Ophthalmic Drugs Market Attractiveness Index
• 10.3 Europe Ophthalmic Drugs Market by Country, 2025, 2030 & 2035 (US$ Billion)
• 10.5 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Country
• 10.6 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Type
• 10.7 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
• 10.8 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Indications
• 10.9 Europe Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
• 10.10 Germany Ophthalmic Drugs Market Analysis
• 10.11 France Ophthalmic Drugs Market Analysis
• 10.12 UK Ophthalmic Drugs Market Analysis
• 10.13 Italy Ophthalmic Drugs Market Analysis
• 10.14 Spain Ophthalmic Drugs Market Analysis
• 10.15 Netherlands Ophthalmic Drugs Market Analysis
• 10.16 Switzerland Ophthalmic Drugs Market Analysis
• 10.17 Rest of Europe Ophthalmic Drugs Market Analysis

11 Asia Pacific Ophthalmic Drugs Market Analysis

• 11.1 Key Findings
• 11.2 Asia Pacific Ophthalmic Drugs Market Attractiveness Index
• 11.3 Asia Pacific Ophthalmic Drugs Market by Country, 2025, 2030 & 2035 (US$ Billion)
• 11.4 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Country
• 11.5 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Type
• 11.6 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
• 11.7 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Indications
• 11.9 Asia Pacific Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
• 11.10 Japan Ophthalmic Drugs Market Analysis
• 11.11 China Ophthalmic Drugs Market Analysis
• 11.12 India Ophthalmic Drugs Market Analysis
• 11.13 Australia Ophthalmic Drugs Market Analysis
• 11.14 South Korea Ophthalmic Drugs Market Analysis
• 11.15 Malaysia Ophthalmic Drugs Market Analysis
• 11.16 Singapore Ophthalmic Drugs Market Analysis
• 11.17 Rest of Asia Pacific Ophthalmic Drugs Market Analysis

12 Latin America Ophthalmic Drugs Market Analysis

• 12.1 Key Findings
• 12.2 Latin America Ophthalmic Drugs Market Attractiveness Index
• 12.3 Latin America Ophthalmic Drugs Market by Country, 2025, 2030 & 2035 (US$ Billion)
• 12.4 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Country
• 12.5 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Type
• 12.6 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
• 12.7 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Indications
• 12.8 Latin America Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
• 12.9 Brazil Ophthalmic Drugs Market Analysis
• 12.10 Argentina Ophthalmic Drugs Market Analysis
• 12.11 Mexico Ophthalmic Drugs Market Analysis
• 12.12 Chile Ophthalmic Drugs Market Analysis
• 12.13 Rest of Latin America Ophthalmic Drugs Market Analysis

13 MEA Ophthalmic Drugs Market Analysis

• 13.1 Key Findings
• 13.2 MEA Ophthalmic Drugs Market Attractiveness Index
• 13.3 MEA Ophthalmic Drugs Market by Country, 2025, 2030 & 2035 (US$ Billion)
• 13.5 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Country
• 13.6 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Type
• 13.7 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Distribution Channel
• 13.8 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Indications
• 13.9 MEA Ophthalmic Drugs Market Size Estimation and Forecast by Route of Administration
• 13.10 GCC Ophthalmic Drugs Market Analysis
• 13.11 South Africa Ophthalmic Drugs Market Analysis
• 13.12 Rest of MEA Ophthalmic Drugs Market Analysis

14 Company Profiles

• 14.1 Strategic Outlook
• 14.2 Novartis AG
  • 14.2.1 Company Snapshot
  • 14.2.2 Company Overview
  • 14.2.3 Financial Analysis
    • 14.2.3.1 Net Revenue, 2018-2023
    • 14.2.3.2 Regional Market Shares, 2023
    • 14.2.3.3 R&D Expense, 2018-2023
  • 14.2.4 Product Benchmarking
  • 14.2.5 Strategic Outlook
• 14.3 Bayer AG
  • 14.3.1 Company Snapshot
  • 14.3.2 Company Overview
  • 14.3.3 Financial Analysis
    • 14.3.3.1 Net Revenue, 2018-2023
    • 14.3.3.2 Regional Market Shares, 2023
    • 14.3.3.3 Business Segment Market Shares, 2023
    • 14.3.3.4 R&D Expense, 2018-2023
  • 14.3.4 Product Benchmarking
  • 14.3.5 Strategic Outlook
• 14.4 Pfizer Inc.
  • 14.4.1 Company Snapshot
  • 14.4.2 Company Overview
  • 14.4.3 Financial Analysis
    • 14.4.3.1 Revenue, 2018-2023
    • 14.4.3.2 Regional Market Shares, 2023
    • 14.4.3.3 Business Segment Market Shares, 2023
    • 14.4.3.4 R&D Expense, 2018-2023
  • 14.4.4 Product Benchmarking
• 14.5 Bausch + Lomb Corporation
  • 14.5.1 Company Snapshot
  • 14.5.2 Company Overview
  • 14.5.3 Financial Analysis
    • 14.5.3.1 Revenue, 2020-2023
    • 14.5.3.2 R&D Expense, 2020-2023
  • 14.5.4 Product Benchmarking
  • 14.5.5 Strategic Outlook
• 14.6 Santen Pharmaceutical Co., Ltd.
  • 14.6.1 Company Snapshot
  • 14.6.2 Company Overview
  • 14.6.3 Financial Analysis
    • 14.6.3.1 Revenue, 2018-2023
    • 14.6.3.2 Regional Market Shares, 2023
  • 14.6.4 Product Benchmarking
  • 14.6.5 Strategic Outlook
• 14.7 Johnson & Johnson Services, Inc.
  • 14.7.1 Company Snapshot
  • 14.7.2 Company Overview
  • 14.7.3 Financial Analysis
    • 14.7.3.1 Revenue, 2018-2023
    • 14.7.3.2 Regional Market Shares, 2023
    • 14.7.3.3 Business Segment Market Shares, 2023
    • 14.7.3.4 R&D Expense, 2018-2023
  • 14.7.4 Product Benchmarking
  • 14.7.5 Strategic Outlook
• 14.9 Regeneron Pharmaceuticals Inc.
  • 14.9.1 Company Snapshot
  • 14.9.2 Company Overview
  • 14.9.3 Financial Analysis
    • 14.9.3.1 Revenue, 2018-2023
    • 14.9.3.2 R&D Expense, 2018-2023
  • 14.9.4 Product Benchmarking
  • 14.9.5 Strategic Outlook
• 14.10 AbbVie Inc.
  • 14.10.1 Company Snapshot
  • 14.10.2 Company Overview
  • 14.10.3 Financial Analysis
    • 14.10.3.1 Revenue, 2018-2023
    • 14.10.3.2 Regional Market Shares, 2023
    • 14.10.3.3 Business Segment Market Shares, 2023
    • 14.10.3.4 R&D Expense, 2018-2023
  • 14.10.4 Product Benchmarking
  • 14.10.5 Strategic Outlook
• 14.11 F. Hoffmann-La Roche Ltd
  • 14.11.1 Company Snapshot
  • 14.11.2 Company Overview
  • 14.11.3 Financial Analysis
    • 14.11.3.1 Revenue, 2018-2023
    • 14.11.3.2 Business Segment Market Shares, 2023
    • 14.11.3.3 R&D Expense, 2018-2023
  • 14.11.4 Product Benchmarking
  • 14.11.5 Strategic Outlook
• 14.12 Teva Pharmaceutical Industries Ltd.
  • 14.12.1 Company Snapshot
  • 14.12.2 Company Overview
  • 14.12.3 Financial Analysis
    • 14.12.3.1 Revenue, 2018-2023
    • 14.12.3.2 Regional Market Shares, 2023
    • 14.12.3.3 R&D Expense, 2018-2023
  • 14.12.4 Product Benchmarking
  • 14.12.5 Strategic Outlook
• 14.13 Apellis Pharmaceuticals
  • 14.13.1 Company Snapshot
  • 14.13.2 Company Overview
  • 14.13.3 Financial Analysis
    • 14.13.3.1 Revenue, 2020-2023
  • 14.13.4 Product Benchmarking
  • 14.13.5 Strategic Outlook
• 14.14 Novaliq GmbH
  • 14.14.1 Company Snapshot
  • 14.14.2 Company Overview
  • 14.14.3 Product Benchmarking
  • 14.14.4 Strategic Outlook
• 14.15 Alimera Sciences
  • 14.15.1 Company Snapshot
  • 14.15.2 Company Overview
  • 14.15.3 Financial Analysis
    • 14.15.3.1 Revenue, 2018-2023
    • 14.15.3.2 R&D Expense, 2018-2023
    • 14.15.3.3 Regional Market Shares, 2023
  • 14.15.4 Product Benchmarking
  • 14.15.5 Strategic Outlook
• 14.16 EyeBio
  • 14.16.1 Company Snapshot
  • 14.16.2 Company Overview
  • 14.16.3 Product Benchmarking
  • 14.16.4 Strategic Outlook
• 14.17 SpliceBio
  • 14.17.1 Company Snapshot
  • 14.17.2 Company Overview
  • 14.17.3 Product Benchmarking
  • 14.17.4 Strategic Outlook
• 14.18 Breye Therapeutics ApS
  • 14.18.1 Company Snapshot
  • 14.18.2 Company Overview
  • 14.18.3 Product Benchmarking
  • 14.18.4 Strategic Outlook
• 14.19 Nicox
  • 14.19.1 Company Snapshot
  • 14.19.2 Company Overview
  • 14.19.3 Financial Analysis
    • 14.19.3.1 Net Revenue, 2019-2023
  • 14.19.5 Product Benchmarking
  • 14.19.6 Strategic Outlook
• 14.20 Alcon
  • 14.20.1 Company Snapshot
  • 14.20.2 Company Overview
  • 14.20.3 Financial Analysis
    • 14.20.3.1 Net Revenue, 2018-2023
    • 14.20.3.2 Business Segment Market Shares, 2023
    • 14.20.3.3 Regional Market Shares, 2023
    • 14.20.3.4 R&D Expense, 2018-2023
  • 14.20.4 Product Benchmarking
  • 14.20.5 Strategic Outlook
• 14.21 Viatris Inc.
  • 14.21.1 Company Snapshot
  • 14.21.2 Company Overview
  • 14.21.3 Financial Analysis
    • 14.21.3.1 Net Revenue, 2018-2023
    • 14.21.3.2 Regional Market Shares, 2023
    • 14.21.3.3 R&D Expense, 2018-2023
  • 14.21.4 Product Benchmarking
  • 14.21.5 Strategic Outlook
• 14.22 Sun Pharmaceutical Industries Ltd.
  • 14.22.1 Company Snapshot
  • 14.22.2 Company Overview
  • 14.22.3 Financial Analysis
    • 14.22.3.1 Net Revenue, 2018-2023
  • 14.22.4 Product Benchmarking

15 Conclusion and Recommendations

• 15.1 Concluding Remarks from Visiongain
• 15.2 Recommendations for Market Players